believe that this treatment schedule is worth testing in patients with other cancers in which a biologic activity of retinoids is involved. 
Failure of Pretreatment With Intravenous Folic Acid to Alter the Cumulative Hematologic Toxicity of Lometrexol
Treatment with lometrexol, an inhibitor of de novo purine synthesis, is complicated by severe stomatitis and cumulative pancytopenia {1-4). Since maximal antitumor effects in mice required normal rather than depleted folate stores (5), clinical trials later included folate repletion (6) (7) (8) . Daily oral folic acid and lometrexol (up to 5 mg/m 2 ) given twice weekly were well tolerated (6, 7) . In a trial stopped early, 2 mg but not 1 mg folic acid with lometrexol (5 mg/m 2 weekly for 3 weeks) minimized stomatitis and thrombocytopenia (8). Other investigators [(fill) ; Natty S, Pagano O, Cavalli F: manuscript submitted for publication] used folates to escalate lometrexol dose. In the study by Sessa et al., oral leucovorin (15 mg, four times daily) was administered on days 7-9, and the lometrexol dose was increased to 60 mg/m 2 every 4 weeks with no grade 3 or 4 toxic effects (National Cancer Institute Common Toxicity Criteria) in six patients. In other studies (8,9), 5 mg folic acid was given daily from 7 days before and 7 days after lometrexol administration, which allowed 170 mg/m 2 lometrexol to be administered every 3 weeks. In another study 5 mg folic acid was continuously administered daily; as a result, lometrexol could be administered at 8 mg/m 2 per week for 12
weeks. Thus, oral leucovorin or folic acid improves tolerance to lometrexol. Responses noted in refractory ovarian cancer and other cancers were not related to the lometrexol dose. In this phase I study, 5 mg folic acid was given intravenously 1 hour before lometrexol every 3 weeks. Dose-limiting toxicity was defined as grade 3 nonhematologic or any grade 4 toxicity, and escalation of the lometrexol dose ceased if two or more patients experienced a dose-limiting toxicity. A sensitive, new high-performance liquid chromatography assay measured pharmacokinetics on the day of therapy; plasma and whole blood levels of lometrexol were ascertained weekly (Synold TW, Xi B, Newman EM, Muggia FM, Doroshow JH: manuscript submitted for publication).
With verification of dose-limiting toxic effects on cycles 2 and 3 of the first level (30 mg/m 2 ), the lometrexol dose was decreased to 15 mg/m 2 . The study was also amended to pretreat patients with 25 mg/m 2 folic acid, which was given intravenously 3 hours before lometrexol (Table 1) •Given every 3 weeks. tOnly four patients received a second course; others had tumor progression.
We conclude that pretreatment with intravenous folic acid does not substantially alter the cumulative toxic effects of lometrexol. This conclusion is reinforced by the finding that, at all dose levels, lometrexol uptake into red blood cells rose steadily and paralleled falls in hematocrit levels (75 The data from the Surveillance, Epidemiology, and End Results (SEER) Program 1 that Curtis et al. present may be biased toward the null value by the failure to consider induction time. This failure is equivalent to assuming that the latent period for tamoxifen-induced gastrointestinal cancers is zero. This assumption results in the dilution of data on truly exposed patients who have had sufficient time to develop the disease under study with data on patients who would be more correctly categorized as unexposed (J). Such dilution is especially important given the short follow-up of the SEER study-the mean duration of follow-up for the tamoxifen-treated group was only 2.8 years (14 358 patients; 39 736 person-years at risk). In contrast, the median follow-up for the patients reported by the Stockholm Breast Cancer Study Group was 8-9 years.
In spite of this bias in follow-up time, the 95% confidence intervals for the odds ratios for stomach and colorectal cancers reported by Curtis et al. overlap those of the Stockholm Breast Cancer Study Group and remain consistent with a 30%^t9% increase in risk of colorectal cancer and as much as a 103% increase in risk of stomach cancer. Clearly, further data obtained from patients exposed to tamoxifen for longer periods will be required before we can dismiss the possibility of an increase in the risk of gastrointestinal cancers due to this drug.
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